CTSV (cathepsin V) promotes bladder cancer progression by increasing NF-κB activity

References

• Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424.
   PubMed Web of Science ®Google Scholar
• Castelao JE, Yuan JM, Skipper PL, et al. Gender- and smoking-related bladder cancer risk. J Natl Cancer Inst. 2001;93:538–545.
   PubMed Web of Science ®Google Scholar
• Teleka S, Haggstrom C, Nagel G, et al. Risk of bladder cancer by disease severity in relation to metabolic factors and smoking: a prospective pooled cohort study of 800,000 men and women. Int J Cancer. 2018;143:3071–3082.
   PubMed Web of Science ®Google Scholar
• Aiken W, Brown M, Morrison B, et al. Cigarette smoking and bladder cancer: are people aware of the risk? BJU Int. 2015;115:4.
   Web of Science ®Google Scholar
• Alberg AJ, Kouzis A, Genkinger JM, et al. A prospective cohort study of bladder cancer risk in relation to active cigarette smoking and household exposure to secondhand cigarette smoke. Am J Epidemiol. 2007;165:660–666.
   PubMed Web of Science ®Google Scholar
• Boffetta P. Tobacco smoking and risk of bladder cancer. Scand J Urol Nephrol. 2008;42:45–54.
   Web of Science ®Google Scholar
• Conde VR, Oliveira PF, Nunes AR, et al. The progression from a lower to a higher invasive stage of bladder cancer is associated with severe alterations in glucose and pyruvate metabolism. Exp Cell Res. 2015;335:91–98.
   PubMed Web of Science ®Google Scholar
• Stokkevag CH, Engeseth GM, Hysing LB, et al. Risk of radiation-induced secondary rectal and bladder cancer following radiotherapy of prostate cancer. Acta Oncol. 2015;54:1317–1325.
   PubMed Web of Science ®Google Scholar
• Olsson CA. Bladder cancer risk following primary and adjuvant external beam radiation for prostate cancer - editorial comment. J Urol. 2008;179:S10–S1.
   Web of Science ®Google Scholar
• Zhang Q, Liu Y, Chen P, et al. Solute carrier family 12 member 8 (SLC12A8) is a potential biomarker and related to tumor immune cell infiltration in bladder cancer. Bioengineered. 2021;12:4946–4961.
   PubMed Web of Science ®Google Scholar
• Nabavizadeh R, Bobrek K, Master VA. Risk stratification for bladder cancer: biomarkers of inflammation and immune activation. Urol Oncol-Semin Ori. 2020;38:706–712.
   PubMed Web of Science ®Google Scholar
• Marshall CH, Dardari Z, Cainzos-Achirica M, et al. Exercise and inflammation on the risk of cancer. Cancer Res. 2019;80:79.
   PubMed Web of Science ®Google Scholar
• Thompson PA, Khatami M, Baglole CJ, et al. Environmental immune disruptors, inflammation and cancer risk. Carcinogenesis. 2015;36:S232–S53.
   PubMed Web of Science ®Google Scholar
• Colotta F, Allavena P, Sica A, et al. Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis. 2009;30:1073–1081.
   PubMed Web of Science ®Google Scholar
• Baird AM, Gray S, O’Byrne K. A model of chronic inflammation affects the invasive capacity and induces several hallmarks of cancer in a normal bronchial epithelial cell line. J Thorac Oncol. 2013;8:S741–S.
   Web of Science ®Google Scholar
• Bredholt G, Mannelqvist M, Stefansson IM, et al. Tumor necrosis is an important hallmark of aggressive endometrial cancer and associates with hypoxia, angiogenesis and inflammation responses. Oncotarget. 2015;6:39676–39691.
   PubMedGoogle Scholar
• Virchow R. Nutrition classics - lecture 16 atheromatous affection of arteries (reprint). Nutr Rev. 1989;47:23–25.
   PubMed Web of Science ®Google Scholar
• Lan M, Lu WP, Zou TT, et al. Role of inflammatory microenvironment: potential implications for improved breast cancer nano-targeted therapy. Cell Mol Life Sci. 2021;78:2105–2129.
   PubMed Web of Science ®Google Scholar
• Maynard JP, De Marzo AM, Sfanos KS. The inflammatory microenvironment in prostate cancer racial disparities. Cancer Epidem Biomar. 2018;27:136.
   Web of Science ®Google Scholar
• Tiwari RK, Ben Rahoma G, Tuli N, et al. Novel targets of breast cancer associated with inflammatory tumor microenvironment. Cancer Res. 2018;1124:78.
   Google Scholar
• Zhang YQ, Zhang GF, Chen L, et al. Modulation of the inflammatory tumor microenvironment: a new approach for photothermal-synergized cancer immunotherapy. Nanomedicine-Uk. 2019;14:2101–2104.
   PubMed Web of Science ®Google Scholar
• Zhang SJ, Yang X, Wang L, et al. Interplay between inflammatory tumor microenvironment and cancer stein cells (Review). Oncol Lett. 2018;16:679–686.
   PubMed Web of Science ®Google Scholar
• Bromme D, Li ZQ, Barnes M, et al. Human cathepsin V functional expression, tissue distribution, electrostatic surface potential, enzymatic characterization, and chromosomal localization. Biochemistry. 1999;38:2377–2385.
   PubMed Web of Science ®Google Scholar
• Chazeirat T, Denamur S, Bojarski KK, et al. The abnormal accumulation of heparan sulfate in patients with mucopolysaccharidosis prevents the elastolytic activity of cathepsin V. Carbohyd Polym. 2021;117261:253.
   Google Scholar
• Adachi W, Kawamoto S, Ohno I, et al. Isolation and characterization of human cathepsin V: a major proteinase in corneal epithelium. Invest Ophthalmol Vis Sci. 1998;39:1789–1796.
   PubMed Web of Science ®Google Scholar
• Adachi W, Kawasaki S, Kinoshita S, et al. Localization of cathepsin V protein in normal cornea. Invest Ophthalmol Vis Sci. 1999;40:S392–S.
   PubMed Web of Science ®Google Scholar
• Toss M, Miligy I, Gorringe K, et al. Prognostic significance of cathepsin V (CTSV/CTSL2) in breast ductal carcinoma in situ. J Clin Pathol. 2020;73:76–82.
   PubMed Web of Science ®Google Scholar
• Sereesongsaeng N, McDowell SH, Burrows JF, et al. Cathepsin V suppresses GATA3 protein expression in luminal A breast cancer. Breast Cancer Res. 2020;22:22.
   PubMed Web of Science ®Google Scholar
• Wang CH, Wang LK, Wu CC, et al. Cathepsin V mediates the tazarotene-induced gene 1-induced reduction in invasion in colorectal cancer cells. Cell Biochem Biophys. 2020;78:483–494.
   PubMed Web of Science ®Google Scholar
• Santamaria I, Velasco G, Cazorla M, et al. Cathepsin L2, a novel human cysteine proteinase produced by breast and colorectal carcinomas. Cancer Res. 1998;58:1624–1630.
   PubMed Web of Science ®Google Scholar
• Schilling DM, Ahlquist DA, Roche PC. Cathepsin L2 overexpression in colorectal neoplasia. Gastroenterology. 1999;116:A370–A.
   Web of Science ®Google Scholar
• Al-Hashimi A, Venugopalan V, Sereesongsaeng N, et al. Significance of nuclear cathepsin V in normal thyroid epithelial and carcinoma cells. Bba-Mol Cell Res. 2020;118846:1867.
   Google Scholar
• Yasuda Y, Li ZQ, Greenbaum D, et al. Cathepsin V, a novel and potent elastolytic activity expressed in activated macrophages. J Biol Chem. 2004;279:36761–36770.
   PubMed Web of Science ®Google Scholar
• Jing JS, Wang SC, Ma JM, et al. Elevated CTSL2 expression is associated with an adverse prognosis in hepatocellular carcinoma. Int J Clin Exp Patho. 2018;11:4035–4043.
   PubMed Web of Science ®Google Scholar
• Hagemann S, Gunther T, Dennemarker J, et al. The human cysteine protease cathepsin V can compensate for murine cathepsin L in mouse epidermis and hair follicles. Eur J Cell Biol. 2004;83:775–780.
   PubMed Web of Science ®Google Scholar
• Chen NN, Seiberg M, Lin CB. Cathepsin L2 levels inversely correlate with skin color. J Invest Dermatol. 2006;126:2345–2347.
   PubMed Web of Science ®Google Scholar
• Noda S, Asano Y, Tada Y, et al. Decreased cathepsin V levels in the sera and skin of patients with systemic sclerosis. J Invest Dermatol. 2011;131:S29–S.
   Web of Science ®Google Scholar
• Marques EF, Vieira PC, Severino RP. Acridone alkaloids as inhibitors of cathepsin L and V. Quim Nova. 2016;39:58–62.
   Web of Science ®Google Scholar
• Sarria ALF, Silva TL, de Oliveira JM, et al. Dimeric chalcones derivatives from myracrodruon urundeuva act as cathepsin V inhibitors. Phytochemistry. 2018;154:31–38.
   PubMed Web of Science ®Google Scholar
• Hackley CR. A novel set of Cas9 fusion proteins to stimulate homologous recombination: cas9-HRs. CRISPR J. 2021;4:253–263.
   PubMedGoogle Scholar
• Ban Y, Tan P, Cai J, et al. LNCAROD is stabilized by m6A methylation and promotes cancer progression via forming a ternary complex with HSPA1A and YBX1 in head and neck squamous cell carcinoma. Mol Oncol. 2020;14:1282–1296.
   PubMed Web of Science ®Google Scholar
• Rao X, Huang X, Zhou Z, et al. An improvement of the 2^(-delta CT) method for quantitative real-time polymerase chain reaction data analysis. Biostat Bioinforma Biomath. 2013;3:71–85.
   PubMedGoogle Scholar
• Zhang MH, Zhang HH, Du XH, et al. UCHL3 promotes ovarian cancer progression by stabilizing TRAF2 to activate the NF-kappa B pathway. Oncogene. 2020;39:322–333.
   PubMed Web of Science ®Google Scholar
• Ni D, Yi Q, Liu J, et al. A1CF-promoted colony formation and proliferation of RCC depends on DKK1-MEK/ERK signal axis. Gene. 2020;730:144299.
   PubMed Web of Science ®Google Scholar
• Cabrita I, Kraus A, Scholz JK, et al. Cyst growth in ADPKD is prevented by pharmacological and genetic inhibition of TMEM16A in vivo. Nat Commun. 2020;11:4320.
   PubMed Web of Science ®Google Scholar
• Wang LL, Feng B, Zhu S. miR-27b-3p down-regulation prevents hypoxia-induced cardiomyocyte apoptosis through regulating yes-associated protein 1 (YAP1) expression. J Biomater Tissue Eng. 2021;977:948–956.
   Web of Science ®Google Scholar
• Daza J, Charap A, Wiklund PN, et al. Role of the innate immune system in the development, progression, and therapeutic response of bladder cancer. Eur Urol Focus. 2020;6:650–652.
   PubMedGoogle Scholar
• Li SJ, Zhao K, Jin YL, et al. Relapse and prognosis of non-muscle invasive bladder cancer after combined HOLRBT with sunitinib and TGC perfusion chemotherapy. Cancer Biother Radio. 2020;35:563–569.
   PubMed Web of Science ®Google Scholar
• Tang HM, Kan LJ, Ou T, et al. Development of a novel prognostic signature for predicting the overall survival of bladder cancer patients. Biosci Rep. 2020;BSR20194432:40.
   Google Scholar
• Jing J, Wang S, Ma J, et al. Elevated CTSL2 expression is associated with an adverse prognosis in hepatocellular carcinoma. Int J Clin Exp Pathol. 2018;11:4035–4043.
   PubMed Web of Science ®Google Scholar
• Penson RT, Kronish K, Duan Z, et al. Cytokines IL-1 beta, IL-2, IL-6, IL-8, MCP-1, GM-CSF and TNF alpha in patients with epithelial ovarian cancer and their relationship to treatment with paclitaxel. Int J Gynecological Cancer. 2000;10:33–41.
   PubMed Web of Science ®Google Scholar
• Leng Y, Chen R, Chen R, et al. HMGB1 mediates homocysteine-induced endothelial cells pyroptosis via cathepsin V-dependent pathway. Biochem Biophys Res Commun. 2020;532:640–646.
   PubMed Web of Science ®Google Scholar
• Swindell WR, Bojanowski K, Chaudhuri RK. A zingerone analog, acetyl zingerone, bolsters matrisome synthesis, inhibits matrix metallopeptidases, and represses IL-17A target gene expression. J Invest Dermatol. 2020;140:602–14 e15.
   PubMed Web of Science ®Google Scholar
• Rayet B, Gelinas C. Aberrant rel/nfkb genes and activity in human cancer. Oncogene. 1999;18:6938–6947.
   PubMed Web of Science ®Google Scholar
• Yousefi H, Momeny M, Poursheykhani A, et al. Nfkb signaling pathway as a therapeutic target in chemoresistant ovarian cancer. Int J Gynecological Cancer. 2017;27:1727.
   Web of Science ®Google Scholar